BioRestorative Therapies Statistics
Total Valuation
BRTX has a market cap or net worth of $3.35 million. The enterprise value is -$212,878.
| Market Cap | 3.35M |
| Enterprise Value | -212,878 |
Important Dates
The next estimated earnings date is Wednesday, November 11, 2026, after market close.
| Earnings Date | Nov 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BRTX has 1.27 million shares outstanding. The number of shares has increased by 38.49% in one year.
| Current Share Class | 1.27M |
| Shares Outstanding | 1.27M |
| Shares Change (YoY) | +38.49% |
| Shares Change (QoQ) | +81.89% |
| Owned by Insiders (%) | 3.24% |
| Owned by Institutions (%) | 15.00% |
| Float | 1.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 9.26 |
| Forward PS | 1.83 |
| PB Ratio | 1.09 |
| P/TBV Ratio | 1.32 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.35, with a Debt / Equity ratio of 0.01.
| Current Ratio | 2.35 |
| Quick Ratio | 2.23 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -241.14% and return on invested capital (ROIC) is -193.30%.
| Return on Equity (ROE) | -241.14% |
| Return on Assets (ROA) | -118.81% |
| Return on Invested Capital (ROIC) | -193.30% |
| Return on Capital Employed (ROCE) | -470.16% |
| Weighted Average Cost of Capital (WACC) | 8.23% |
| Revenue Per Employee | $25,562 |
| Profits Per Employee | -$789,756 |
| Employee Count | 14 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -91.22% in the last 52 weeks. The beta is 0.74, so BRTX's price volatility has been lower than the market average.
| Beta (5Y) | 0.74 |
| 52-Week Price Change | -91.22% |
| 50-Day Moving Average | 4.22 |
| 200-Day Moving Average | 9.13 |
| Relative Strength Index (RSI) | 27.42 |
| Average Volume (20 Days) | 31,853 |
Short Selling Information
The latest short interest is 37,641, so 2.95% of the outstanding shares have been sold short.
| Short Interest | 37,641 |
| Short Previous Month | 99,687 |
| Short % of Shares Out | 2.95% |
| Short % of Float | 3.11% |
| Short Ratio (days to cover) | 0.14 |
Income Statement
In the last 12 months, BRTX had revenue of $357,870 and -$11.06 million in losses. Loss per share was -$19.51.
| Revenue | 357,870 |
| Gross Profit | 329,550 |
| Operating Income | -14.23M |
| Pretax Income | -11.06M |
| Net Income | -11.06M |
| EBITDA | -14.01M |
| EBIT | -14.23M |
| Loss Per Share | -$19.51 |
Balance Sheet
The company has $3.59 million in cash and $28,774 in debt, with a net cash position of $3.56 million or $2.80 per share.
| Cash & Cash Equivalents | 3.59M |
| Total Debt | 28,774 |
| Net Cash | 3.56M |
| Net Cash Per Share | $2.80 |
| Equity (Book Value) | 3.03M |
| Book Value Per Share | 2.38 |
| Working Capital | 2.19M |
Cash Flow
In the last 12 months, operating cash flow was -$11.82 million and capital expenditures -$79,669, giving a free cash flow of -$11.90 million.
| Operating Cash Flow | -11.82M |
| Capital Expenditures | -79,669 |
| Depreciation & Amortization | 210,598 |
| Net Borrowing | n/a |
| Free Cash Flow | -11.90M |
| FCF Per Share | -$9.34 |
Margins
| Gross Margin | 92.09% |
| Operating Margin | -3,975.00% |
| Pretax Margin | -3,089.55% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BRTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -38.49% |
| Shareholder Yield | -38.49% |
| Earnings Yield | -333.82% |
| FCF Yield | -359.21% |
Analyst Forecast
The average price target for BRTX is $160.00, which is 5,983.65% higher than the current price. The consensus rating is "Buy".
| Price Target | $160.00 |
| Price Target Difference | 5,983.65% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 105.57% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on September 8, 2026. It was a reverse split with a ratio of 1:20.
| Last Split Date | Sep 8, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
BRTX has an Altman Z-Score of -57.29 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -57.29 |
| Piotroski F-Score | 3 |